Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly

Annamaria Colao, Alberto Cuocolo, Paolo Marzullo, Emanuele Nicolai, Diego Ferone, Luigia Florimonte, Marco Salvatore, Gaetano Lombardi

Research output: Contribution to journalArticle

Abstract

The aim of the study was to investigate the effects of 1-yr treatment with octreotide (OCT) on left ventricular diastolic and systolic function, assessed at rest and during physical exercise by gated blood pool cardiac scintigraphy, in 30 patients with active acromegaly. OCT was initially given at a dose of 0.05-0.1 mg, 3 times daily, and the dose was subsequently increased to achieve GH/insulin-like growth factor I (IGF-I) normalization. Hormone normalization after treatment was considered when basal and/or oral glucose test-suppressed GH values were below 2.5 and 1 μg/L, respectively, and IGF-I values were within the normal range for age. TG evaluate the response to OCT treatment in terms of cardiac performance, the 30 patients were divided into 2 groups on the basis of normalized (in 13 patients) or nonnormalized (in 17 patients) circulating GH and IGF-I levels. At study entry, hypertension was found in 6 patients (20%), abnormal left ventricular diastolic filling was found in 12 patients (40%), and impaired left ventricular ejection fraction was found in 2 patients at rest (6.6%) and in 18 patients at peak exercise (60%). Before OCT treatment, exercise duration ranged from 6-10 min, and exercise workload ranged from 50-125 watts. After 1-yr treatment with OCT, a significant decrease in circulating GH and IGF-I levels was achieved in all patients, but normalization was obtained only in 13 of 30 patients. In patients achieving circulating GH and IGF-I normalization after OCT treatment but not in those with persistently elevated hormone levels, a significant decrease in heart rate, both at rest (from 75.7 ± 3.3 to 66.5 ± 2.9 beats/min; P <0.01) and after exercise (from 137.5 ± 4.9 to 123.7 ± 4.1 beats/min; P <0.01), and a significant increase in left ventricular ejection fraction, both at rest (from 56.5 ± 1.8% to 66.5 ± 2.2%; P <0.01) and after exercise (from 52.6 ± 2.4% to 67.1 ± 1.7%; P <0.01), were found. In the 17 patients who had persistently high circulating GH and IGF-I levels after 1 yr of OCT treatment, left ventricular ejection fraction was unchanged at rest but was significantly reduced after exercise compared to the basal value (from 64.9 ± 2.4% to 57.2 ± 2.6%, P <0.01); systolic blood pressure at rest was significantly increased (from 128.5 ± 4.9 to 141.2 ± 5.4 mm Hg; P <0.05). In these 17 patients, the ejection fraction response to exercise was significantly impaired, mostly in those less than 40 yr of age (from 11.6 ± 3.2% to -0.3 ± 5.6%; P <0.05). In particular, among 9 patients who had a normal response to exercise at study entry, 6 developed an abnormal response after 1 yr. Left ventricular diastolic filling was unchanged by OCT treatment in all patients. Exercise duration (only in young patients from 7.5 ± 0.5 to 9.3 ± 0.7 min; P <0.05) and exercise workload (in all 13 patients from 80.8 ± 6.4 to 92.3 ± 5.9 watts; P <0.05) were significantly increased in the group of patients with normalized GH and IGF levels, but not in the remaining 17 (from 7.6 ± 0.4 to 7.5 ± 0.4 min and from 89.9 ± 5.5 to 84.4 ± 4.5 watts, respectively). In conclusion, the results of the present study indicate that suppression of basal or glucose-suppressed GH levels below 2.5 or 1 μg/L, respectively, together with normalization of plasma IGF-I levels for 1 yr are followed by a significant improvement, but not complete normalization, of left ventricular ejection fraction either at rest or at peak exercise without significant changes in diastolic filling. By contrast, the persistence for 1 yr of elevated hormone levels caused a significant increase in systolic blood pressure and impaired cardiac performance. These data suggest that prolonged suppression of circulating GH and IGF-I levels could normalize cardiac performance and probably reverse the poor prognosis for cardiovascular disease in acromegaly.

Original languageEnglish
Pages (from-to)17-23
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume84
Issue number1
DOIs
Publication statusPublished - 1999

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly'. Together they form a unique fingerprint.

  • Cite this